Lior Carmi1, Uri Alyagon2, Noam Barnea-Ygael2, Joseph Zohar3, Reuven Dar4, Abraham Zangen5. 1. School of Psychological Sciences, Tel Aviv University, Tel Aviv, Israel; Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel. 2. Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel. 3. Tel Aviv University, Sackler Faculty of Medicine, Tel- Aviv, Israel. 4. School of Psychological Sciences, Tel Aviv University, Tel Aviv, Israel. 5. Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel. Electronic address: azangen@bgu.ac.il.
Abstract
BACKGROUND: Obsessive Compulsive Disorder (OCD) is a chronic and disabling disorder with poor response to pharmacological treatments. Converging evidences suggest that OCD patients suffer from dysfunction of the cortico-striato-thalamo-cortical (CSTC) circuit, including in the medial prefrontal cortex (mPFC) and the anterior cingulate cortex (ACC). OBJECTIVE: To examine whether modulation of mPFC-ACC activity by deep transcranial magnetic stimulation (DTMS) affects OCD symptoms. METHODS: Treatment resistant OCD participants were treated with either high-frequency (HF; 20 Hz), low-frequency (LF; 1 Hz), or sham DTMS of the mPFC and ACC for five weeks, in a double-blinded manner. All treatments were administered following symptoms provocation, and EEG measurements during a Stroop task were acquired to examine changes in error-related activity. Clinical response to treatment was determined using the Yale-Brown-Obsessive-Compulsive Scale (YBOCS). RESULTS: Interim analysis revealed that YBOCS scores were significantly improved following HF (n = 7), but not LF stimulation (n = 8), compared to sham (n = 8), and thus recruitment for the LF group was terminated. Following completion of the study, the response rate in the HF group (n = 18) was significantly higher than that of the sham group (n = 15) for at least one month following the end of the treatment. Notably, the clinical response in the HF group correlated with increased Error Related Negativity (ERN) in the Stroop task, an electrophysiological component that is attributed to ACC activity. CONCLUSION: HF DTMS over the mPFC-ACC alleviates OCD symptoms and may be used as a novel therapeutic intervention. Notwithstanding alternative explanations, this may stem from DTMS ability to directly modify ACC activity.
BACKGROUND:Obsessive Compulsive Disorder (OCD) is a chronic and disabling disorder with poor response to pharmacological treatments. Converging evidences suggest that OCDpatients suffer from dysfunction of the cortico-striato-thalamo-cortical (CSTC) circuit, including in the medial prefrontal cortex (mPFC) and the anterior cingulate cortex (ACC). OBJECTIVE: To examine whether modulation of mPFC-ACC activity by deep transcranial magnetic stimulation (DTMS) affects OCD symptoms. METHODS: Treatment resistant OCDparticipants were treated with either high-frequency (HF; 20 Hz), low-frequency (LF; 1 Hz), or sham DTMS of the mPFC and ACC for five weeks, in a double-blinded manner. All treatments were administered following symptoms provocation, and EEG measurements during a Stroop task were acquired to examine changes in error-related activity. Clinical response to treatment was determined using the Yale-Brown-Obsessive-Compulsive Scale (YBOCS). RESULTS: Interim analysis revealed that YBOCS scores were significantly improved following HF (n = 7), but not LF stimulation (n = 8), compared to sham (n = 8), and thus recruitment for the LF group was terminated. Following completion of the study, the response rate in the HF group (n = 18) was significantly higher than that of the sham group (n = 15) for at least one month following the end of the treatment. Notably, the clinical response in the HF group correlated with increased Error Related Negativity (ERN) in the Stroop task, an electrophysiological component that is attributed to ACC activity. CONCLUSION: HF DTMS over the mPFC-ACC alleviates OCD symptoms and may be used as a novel therapeutic intervention. Notwithstanding alternative explanations, this may stem from DTMS ability to directly modify ACC activity.
Authors: Zhi-De Deng; Bruce Luber; Nicholas L Balderston; Melbaliz Velez Afanador; Michelle M Noh; Jeena Thomas; William C Altekruse; Shannon L Exley; Shriya Awasthi; Sarah H Lisanby Journal: Annu Rev Pharmacol Toxicol Date: 2020-01-06 Impact factor: 13.820
Authors: Daniel T Corp; Hannah G K Bereznicki; Gillian M Clark; George J Youssef; Peter J Fried; Ali Jannati; Charlotte B Davies; Joyce Gomes-Osman; Julie Stamm; Sung Wook Chung; Steven J Bowe; Nigel C Rogasch; Paul B Fitzgerald; Giacomo Koch; Vincenzo Di Lazzaro; Alvaro Pascual-Leone; Peter G Enticott Journal: Brain Stimul Date: 2020-08-03 Impact factor: 8.955
Authors: Kara A Johnson; Gordon Duffley; Daria Nesterovich Anderson; Jill L Ostrem; Marie-Laure Welter; Juan Carlos Baldermann; Jens Kuhn; Daniel Huys; Veerle Visser-Vandewalle; Thomas Foltynie; Ludvic Zrinzo; Marwan Hariz; Albert F G Leentjens; Alon Y Mogilner; Michael H Pourfar; Leonardo Almeida; Aysegul Gunduz; Kelly D Foote; Michael S Okun; Christopher R Butson Journal: Brain Date: 2020-08-01 Impact factor: 13.501